Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

About this update from Greenwich Lifesciences, Inc.

[{"type":"text","content":"ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (Nasdaq:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.","length":350,"tagName":"p"},{"type":"text","content":"Access the interview in its entirety at: https://www.redchip.com/assets/access/glsi_access","length":90,"tagName":"p"},{"type":"text","content":"In an exclusive previously recorded interview, Snehal Patel, CEO of Greenwich LifeSciences, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's mission to prevent breast cancer recurrences through GLSI-100, a novel breast cancer vaccine immunotherapy combining the HER2-derived GP2 peptide with GM-CSF. Patel highlights the promising results from a prior Phase II trial showing no metastatic recurrences in immunized patients and details the global expansion of the ongoing Phase III FLAMINGO-01 trial, now active at more than 120 sites across the U.S. and Europe. He also outlines the Company's strategy to accelerate commercialization through advanced manufacturing readiness and strong academic partnerships, positioning GLSI-100 as a potential game-changer in the HER2-positive breast cancer treatment landscape.","length":865,"tagName":"p"},{"type":"text","content":"GLSI is a client of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.","length":116,"tagName":"p"},{"type":"text","content":"About Greenwich LifeSciences, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's websit...

More updates from Greenwich Lifesciences, Inc.